Abstract
Aims and objective: Prime objective was to determine anthropometric, clinical, biochemical profile of type 2 diabetes mellitus in patients attending Bokaro General Hospital.
Method: A hospital based cross sectional study was conducted during March 2010 to June 2012. The study population comprised diabetic subjects attending endocrinology unit of Bokaro General Hospital. Total 126 patients were taken comprising of old and new cases.After taking and recording detailed history including present complains ,past history including duration of diabetes ,history and duration of hypertension, cardiovascular disease, dyslipidemia; personal history and complete anthropometric and physical examination was carried out.
Result : Out of 126 patients about 4 % were <40 years of age, maximum number of patient belonged to age group 41-60, 64% and only 32.6% patient were in elderly group. Mean age was found to be 56.67±8.38. Majority of females fell in the age group of 41 – 60 years (76.59%). Whereas age distribution was almost equal in men and women in 41-60.In both male and female age group only 2.53% ,6.38% were noted to be <40 years of age respectively. p value = < .001 ,Which is statistically significant. The difference between male and female was found to be highly significant (p<0.001) Around 28.58 % patient were non obese .In our study majority of patient were found to be obese (50%) and 21.42 %were observed to be overweight. Most of our patient were found to be obese (with BMI 25.22±3.73) according to the WHO guidelines and the consensus statement for diagnosis of Obesity, Abdominal obesity and the metabolic syndrome for Asian Indians. (Normal BMI: 18-22.9 kg/m2; Overweight: 22-24.9 kg/m2;Obesity: >25 kg/m2).Most of the patients were obese. Overweight patient constituted 26.65%male and 12.76% female. Almost equal number of diabetic males (27.58%)as well as females(29.78%) were having normal BMI. p value<0.04. The difference between male and female was found to be significant (p<0.04). Male patient having central obesity (55%) exceeded males with normal (45%) abdominal circumference. In females majority of them were having central obesity and only 6% females were having normal abdominal girth. Mean waist circumference among females was 92.03±9.85. In comparison more than 90% of female were found to be having central obesity, whereas about half (55%) of males revealed abdominal obesity .Good number of males (45%) were normal around the waist .only 6.38% female were having normal abdominal girth. p value <.001. The difference between male and female was found to be highly significant (p<0.001).
More than half (55%) of our population were having cholesterol within normal limit.
Around 60 % of diabetic patient revealed normal triglyceride level. Only 41 % diabetic showed raised triglyceride level. Out of 126 patients very few diabetics(15%) were having normal HDl. Majority were having low HDL. LDL was well within control in 86% of patients with 82 out of 126 patients LDL less than/equal to 100 mg/dl. About 69 % of total diabetic were suffering from hypertension. Significant percentage of females were found to be having dyslipidemia (91%), whereas about 79% of males were having abnormal lipid profile. The difference between male and female was found to be significant (p<0.03). In our study it was observed that approximately 70% of patients were having Metabolic syndrome and on comparing between male to female percent it was seen that female patient were predominantly suffering from metabolic syndrome. The difference between male and female was found to be highly significant (p<0.001) Out of 126 patients 15 patients were having hypothyroidismIn present study good glycemic control was achieved in 34.17% of males but only 21.27 % of females revealed good control .Equal number of male and females had glycated haemoglobin between 7-9% More than 51% of females and about 39 % of males showed HbA1C above 9%.p value 0.1. The difference between male and female was found to be not significant (p<0.1).
Out of 126 patients 45.56% males and 44.68% females were having diabetic neuropathy Approximately one third (27%) of males and twenty percent females had retinopathy. The difference between male and female was found to be not significant (p value 0.17).One fourth of males 26% and about one fifth of females had nephropathy. Kidney involvement was seen in only 23% of patients .The difference between male and female
was found to be not significant (p value 0.3).In present study out of 126 patients 17 % patient were suffering from coronary heart disease.
Conclusion
In our hospital study although conducted in small number of patients revealed:
1. Most of the patients belonged to age group 40-60.
2. Majority of diabetics were obese, having BMI more than 25 kg/m2
3. Very few new patients were studied in our study presenting with polydipsia, polyuria as common presentation.
4. Majority of our patients were having dyslipidemia, and it was seen that dyslipidemia was significantly preponderant in females.
5. There was dominance of female having metabolic syndrome almost reaching 91% which is much above the findings depicted by other Indian studies, Probably because of limited number of females in our study.
6. Our study revealed the level of glycemic control was near the target given by ADA in almost one third of patients, which can be attributed to comprehensive care imparted by endocrinology unit.
7. Neuropathy, Retinopathy and Nephropatahy, were present in one fourth of the patient and it was seen to be significantly associated with duration of diabetes.
Further study with large number of patient is required to substantiate our study.
Significant Findings of the study
1. Most of the patients belonged to age group 40-60.
2. Majority of diabetics were obese, having BMI more than 25 kg/m2 .
3. Very few new patients were studied in our study presenting with polydipsia, polyuria as common presentation.
4. Majority of our patients were having dyslipidemia, and it was seen that dyslipidemia was significantly preponderant in females..
5. There was dominance of female having metabolic syndrome almost reaching 91% which is much above the findings depicted by other Indian studies, Probably because of limited number of females in our study.
6. Our study revealed the level of glycemic control was near the target given by ADA in almost one third of patients, which can be attributed to comprehensive care imparted by endocrinology unit.
7. Neuropathy, Retinopathy and Nephropatahy, were present in one fourth of the patient and it was seen to be significantly associated with duration of diabetes.
Further study with large number of patient is required to substantiate our study.
Keywords: Profile of Type 2 DM , Metabolic syndrome, hypertension
References
1. Epidemiology of type 2 diabetes: Indian scenario. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. PMID: 17496352[PubMed - indexed for MEDLINE] Indian J Med Res.2007 Mar;125(3):217-30._ )
2. CDC 2003, National Diabetes fact sheet, www.cdc.gov/diabetes/factsheet.htm.
3. Ebrahim S, Kinra S, Bowen L, Andersen E, Ben-Shlomo Y, Lyngdoh T et al. The effect of rural-to-urban migration on obesity and diabetes in India: a crosseectionalstudy. PLoSMed2010;7(4):e1000268(doi:10.1371/journal.pmed.1 000268).
4. Mohan V, Deepa M, Deepa R, Shanthirani CS, FarooqS, Ganesan A et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban south India―the Chennai urban rural epidemiology study (CURES-17). Diabetalogia 2006;49:1175-8.
5. Deepa M, Pradeepa R, Rema M, Mohan A, Deepa R, Shanthirani S, Mohan V. The Chennai urban rural epidemiology study (CURES)—study design and methodology (urban component) (CURES–I). J Assoc Physicians India 2003;51:863-70.
6. Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr RelatDisord2009;7:497-514.
7. (Boden G. Fatty acids and insulin resistance. Diabetes Care. Apr 1996;19(4):394-5)
8. (Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care. Oct 2010;33(10):2225-31) .
9. (Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J ClinEndocrinolMetab. Feb 2011;96(2):447-53).
10. (Krssak M, Winhofer Y, Gobl C, et al. Insulin resistance is not associated with myocardial steatosis in women. Diabetologia. Jul 2011;54(7):1871-8).
11. (Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statintreated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. Nov 2011;28(11):1343-1351).
12. http://www.who.int/mediacentre/factsheets/fs312/en/
13. Mohan v et al Indian J Med Res 125, March 2007, pp 217-230
14. Rao PV, Ushabala P, Seshaiah V, Ahuja MMS, Mather HM. The Eluru survey: prevalence of known diabetes in a rural Indian population
15. Alberti et al the metabolic syndrome – a new world wide definition the lancet 2005, 1059-1062
16. Cameron aj saw prevalence in worldwide population endocrinology and metabolism clinic of north America 2004,351-375
17. Lee wy, jungCH, parjjs, rhee, EJkim e10,11
18. olufadi R, Byrne CD. Clinical and laboratory diagnosis of the metabolic syndrome. J ClinPathol. Jun 2008;61(6):697-706
19. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. Oct 25 2005;112(17):2735-52.
20. Prevalence of Metabolic Syndrome in An Urban Indian Diabetic Population Using The NCEP ATP III Guidelines SP Surana*, DB Shah ,Japi .org:
21. Prevalence of metabolic syndrome in an Indian urban population. Gupta R et al, source : pubmed
22. Dyslipidemia in type 2 diabetes mellitus ,PUBMED, Mooradian et al Nat clinpract endocrinology metabolism 2009 mar ;5(3):150-9 1.
23. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-50.Lakka HM, Laaksonen DE,
24. Lakka TA, et al. The metabolic syndrome and total and cardiovascular mortality in middle-aged men .JAMA 2002; 288: 2709-16.
25. Abdel-Aal NMhttp://www.ncbi.nlm.nih.gov/pubmed?term=AbdelAal%20NM%5 BAuthor%5D & cauthor=true&cauthor_uid=18946566
26. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation presented at: theWorld Health Organization; June 3-5, 1997;Geneva, Switzerland. Publication WHO/NUT/ NCD/98.1.
27. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008;93(11Suppl1):S930.
28. Mayer-Davis EJ, Costacou T. Obesity and sedentary lifestyle: modifiable risk factors for prevention of type2 diabetes. Curr Diabet Rep 2001;1:170-6.
29. Lieberman LS. Dietary, evolutionary, and modernizing influences on the prevalence of type 2 diabetes. Annu Rev Nutr2003;23:345-77.
30. Bener A, Al-Suwaidi J, Al-Jaber K, Al-Marri S, Elbagi IE. Epidemiology of hypertension and its associated risk factors in the Qatari population. J Hum Hypertens2004;18:529-30.
31. Musaiger AO, Al-Mannai MA. Social and lifestyle factors associated with diabetes in the adult Bahraini population. J BiosocSci2002;34:277-81.
32. Gupta R, Gupta VP, Sarna M, et al. Prevalence of coronary heart disease and risk factors in an urban Indian population: Jaipur Heart Watch-2.Indian Heart J 2002;54(1):59-66.
33. Gupta R, Gupta VP, Sarna M, et al. Prevalence of coronary heart disease Gupta R,Misra A. Type 2 diabetes in India: Regional Disparities. Br J Diabetes & Vascular Dis 2007;7:12-16
34. KGMM Alberti et al for the IDF Epidemiology Task Force Consensus Group: Lancet 366:1059, 2005.
35. Singh RB, Bajaj S, Niaz MA, Rastogi SS, Moshiri M. Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. Int J Cardiol1998 ;66:65-72..
36. (ref: feb 2009 issue of journal of clinical endocrinology and metaboloism jcem.endojournals.org)
37. Swersh et alHypertension. 2001 update Apr;37(4):1053-9. pubmed
38. http://www.annals.org/content/138/7/593.full#ref-19
39. University of Milano-Bicocca, San Gerardo Hospital, Department of Clinical Medicine, Via Donizetti 106, I-20052 Monza, Milan, Italy. giuseppe. This email address is being protected from spambots. You need JavaScript enabled to view it.: 15868115 [PubMed - indexed for MEDLINE]
40. UKPDS ,Tight blood pressure control and risk of microvascular and macrovascular complications in type 2 diabetes ,BMJ,1998;317:703-1
41. From UKPDS group study 7 metabolism,1990 39 ,905-12
42. Oxford textbook of endocrinology second edition, 1774
43. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4- 7 yr before clinical diagnosis. Diabetes Care. Jul 1992;15(7):815-9
44. Ref: Raman R et al ,ophthalmology ,2009,feb;116(2):311-8,Epub 2008 dec m2012, pmid 19084275.
45. RemaM,PremkumarS,AnithaB,.Prevalence of diabetic retinopathy in urban India CURES The Chennai urban epidemiology study .Invest opthalmolvis sci2005;46:232833
46. Varma R ,Torres M ,Latino eye study group prevalence of diabetic retinopathy in adults ,ophthalmology 2004,111,1298-306
47. The eye disease prevalence research group..The prevalence of diabetic retinopathy in adults in United states ,Arch ophthalmol 2004;122:552-63
48. Ref:Trevisan R walker,Diabetic nephropathy. In Jamison R willkinson R 2 eds London chapman and hall,1997,551-574
49. Ref:Trevisan R walker, Diabeticnephropathy. In Jamison R willkinson R 2 eds London chapman and hall,1997,551-574
50. Mogensen CE ,definition of diabetic renal disease in IDDM based on renal function test 4th edition,1998, 17-30
51. Modified from National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification and stratification. Am J Kidney Dis 39:suppl 1, 2002.
52. Ramachandran A, Snehalatha C, Mary S, MukeshB, Bhaskar AD, Vijay V. Indian Diabetes Prevention Programme (IDPP): the Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia2006;49:289–97.
53. Heisler M, Pietee JD, Spencer M, Kieffer E, Vijan S. The relationship between knowledge of recent HbA1c values and diabetes care understanding and self management. Diabet Care 2005;28:816–22.
54. (Holmstrom IM, Rosenqvist U. Misunderstandings about illness and treatment among patients with type 2 diabetes. J AdvNurs2005;49:146-54).
55. Maskari F, El-Sadig M. Prevalence of risk factors n for diabetic foot complications. BMC Fam Pract2007;8:59.),
56. (Al-Kaabi J, Al-Maskari F, Saadi H, Afandi B, Parkar H, Nagelkerke N. Assessmen of dietary practices among diabetic patients in the United Arab Emirates. Rev Diabet Stud 2008;5:110-5).
57. Rewers M, Hamman R. Risk factors for noninsulin- dependent diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. Bethesda, Md: National Institutes of Health; 1995. p. 179–220.
58. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity related health risk factors, 2001. JAMA.2003;289(1):76–79.
59. Howard Bv Pathogenesis of diabetic dyslipidemia, Diabetes review 1995,3,423-432
60. Haaris MI hypercholesterolemia in diabetes and glucose intolerance in US people diabetes care 1991 ,366-374
61. christleb AR Treatment selection consideration for the hypertensive diabetic patients, Arch intern med 1990,1167-1174
62. Brown wvhoward Treatment of lipoprotein disorder cardiovascclin 1990 ,157- 176
63. Howard WJ Brown WV Pharmacologic therapy of hypercholesterolemia curropincardiol 1989 ,525-541
64. Howard BV robins DC sievers ML et al LDL cholesterol strong predictor of CHD in diabetic individuals with low LDL 2000;830-835
65. Howard BV ,Robbins DC, SieversML, et al, strong predictor of CHD , In diabetic individual with insulin resistance and low LDL, 2000;830-835
66. Tesfays S Boulton AJ eds. Diabetic neuropathy, oxford :oxford university press 2009
67. Shaw JE ,ZimmetPZ.The epidemiology of diabetic neuropathy Diabetes Rev 1999;7:245-252
68. Tesfaye S ,Stephens l ,Fuller J; et al; the EURODIAB IDDN complication study Diabetologia,1996,39:1377-84
69. TesfayeS, Chaturvedi N, Eaton SEM, Witte D, Ward JD, Fuller J VASCULAR RISK FACTORS AND DIABETIC NEUROPATHY NEJM 2005;352:341-50).
70. Watkins PJ, Edmonds ME ,Clinical feature of diabetic neuropathy In pickup j williams, Textbook of diabetes Vol 2 oxford ,Blackwell science,1997:50.1-50.20)
71. World Health Organization. World Health Statistics. Department of Measurement & Health Information Systems of the Information, Evidence and Research Cluster. Geneva: WHO Press; 2008. p. 29-31.592 INDIAN J MED RES, NOVEMBER 2010
72. Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol1976; 37 : 269-82.
73. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 : 937-52.
74. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008; 94 : 16-26
75. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991; 81 : 1158-62.
76. Geiss LS, Herman WM, Smith PJ. Mortality in non-insulin-dependent diabetes. In: National Diabetes Data Group, editor. Diabetes in America, 2nd ed. Bethesda, MD: NIH & NIDDK: National Diabetes Information Clearing house; 1995. p. 233- 55
77. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298 765-75.
78. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16 : 434-44.
79. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus wth total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007; 167 : 1145-51.
80. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007; 125 : 217-30.
81. McKeigue PM, Ferrie JE, Pierpoint T, Marmot MG. Association of early-onset coronary heart disease in South Asian men with glucose intolerance and hyperinsulinemia. Circulation 1993; 87 : 152-61.
82. Enas EA, Mehta J. Malignant coronary artery disease in young Asian Indians: thoughts on pathogenesis, prevention, and therapy. Coronary Artery Disease in Asian Indians (CADI) Study. ClinCardiol1995; 18 : 131-5.
83. International Diabetes Federation (IDF). Diabetes atlas 4th ed. 2009. Available at: www.diabetesatlas.org.
84. Srikanth S, Deedwania P. Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach. CardiolClin2005; 23 : 193- 210.
85. Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med 2003; 115 (Suppl 8A): 6S-11S
86. Reddy ks, Prabhakarn d ,Chaturvedi v et al ,tm 2006 methods for establishing survillence system for cardiovascular disease in Indian industrial population: 84,461-469.
87. Raheja BS, Kapur A, Bhoraskar A, Sathe SR, Jorgensen LN, Moorthi SR, Pendsey S, Sahay BK. DiabCare Asia—India Study:diabetes care in India—current status. J Assoc Physicians India 2001;49:717-22
DOI: http://dx.doi.org/10.18535/jmscr/v4i4.56
